Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, July 2, 2022

Promising Action of Cannabinoids on ER Stress-Mediated Neurodegeneration: An In Silico Investigation

 Don't read between the lines and think that cannabidiol or marijuana would suffice in duplicating the benefits. You're going to have to wait 50 years before anything gets defined for layperson use. Hope you last that long.

Promising Action of Cannabinoids on ER Stress-Mediated Neurodegeneration: An In Silico Investigation

Volume 41, Issue 4, 2022, pp. 39-54
DOI: 10.1615/JEnvironPatholToxicolOncol.2022040055
Get accessGet access
Fathima Hajee Basha
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India
Mohammad Waseem
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India
Hemalatha Srinivasan
School of Life Sciences, B.S Abdur Rahman Crescent Institute of Science of Technology, Vandalur, Chennai 600048, Tamil Nadu, India

ABSTRACT

Neurodegeneration has been recognized as a clinical episode characterized by neuronal death, including dementia, cognitive impairment and movement disorder. Most of the neurodegenerative deficits, via clinical symptoms, includes common pathogenic features as protein misfolding and aggregation. Therefore, the focus highlights the cellular organelle endoplasmic reticulum (ER) critically linked with the quality control and protein homeostasis. Unfolded protein response (UPR) or ER stress have also been considered as hallmarks for neurodegenerative disorders. It has been implicated that the levels of endocannabinoids (ECB) could rise at the platform of neurodegeneration. In addition, phytocannabinoids (PCB) including cannabidiol (CBD) could also initiate the IRE1, PERK, XBP-1, and ATF6, pathways that could lead to the degradation of the misfolded proteins and termination of protein translation. Thus, our aim was to determine if cannabinoids bind to these ER arm proteins involved in UPR by molecular docking and therefore determine its drug resemblance through ADME analysis. In our study, three cannabinoid receptors (CB1, CB2, and CB3) were considered to demonstrate their neuroprotective actions. The chosen ligands were screened as PCB (Δ9-tetrahydrocannabinol or THC), CBD, and two ECB, anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The current findings have advocated that the cannabinoids and their molecular targets have shown considerable binding and their ADME properties also reveals that they possess moderate drug-like properties making it as a valuable option for the treatment and management of neurodegenerative diseases.

KEY WORDS: neurodegeneration, ER stress, cannabinoids, molecular docking, ADME
REFERENCES

  1. Batista P, Pereira A. Quality of life in patients with neuro-degenerative diseases. J Neurol Neurosci. 2016;7(1):1-7.

  2. Faden AI, Stoica B. Neuroprotection: Challenges and opportunities. Arch Neurol. 2007;64(6):794-800.

  3. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S207-9.

  4. Basha FH, Waseem M, Srinivasan H. Cellular and molecular mechanism in neurodegeneration: Possible role of neuroprotectants. Cell Biochem Funct. 2021;39(5): 11. 613-22.

  5. Marsh AP. Molecular mechanisms of proteinopathies across neurodegenerative disease: A review. Neurol Res Pract. 2019;1(1):1-7.

  6. Watson RR, Preedy VR. Bioactive nutraceuticals and dietary supplements in neurological and brain disease. In: Watson R, Preedy V, editors. Prevention therapy. Academic Press; 2015. p. 495-500.

  7. Xiang C, Wang Y, Zhang H, Han F. The role of endoplasmic reticulum stress in neurodegenerative disease. Apoptosis. 2017;22(1):1-26.

  8. Lou G, Palikaras K, Lautrup S, Scheibye-Knudsen M, Tavernarakis N, Fang EF. Mitophagy and neuroprotection. Trends Mol Med. 2020;26(1):8-20.

  9. Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017;13(8): 477-91.

  10. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: Pathogenesis and therapy. Brain Pathol. 2018;28(1):3-13.

  11. Adams CJ, Kopp MC, Larburu N, Nowak PR, Ali MMU. Structure and molecular mechanism of ER stress signaling by the unfolded protein response signal activator IRE1. Front Mol Biosci. 2019;6:11.

  12. Scheper W, Hoozemans JJM. The unfolded protein response in neurodegenerative diseases: A neuropathological perspective. Acta Neuropathol. 2015;130(3):315-31.

  13. Milano W, Capasso A. Neuroprotection by cannabinoids in neurodegenerative diseases. Alzheimer's. Dement Cogn Neurol. 2018;2(1):1-7.

  14. Giammalva GR, Iacopino DG, Graziano F, Guli C, Pino MA, Maugeri R. Clinical and radiological features of Forestier's disease presenting with dysphagia. Surg Neurol Int. 2018;28;9:236.

  15. Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem. 2017;142(5):624-48.

  16. Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol. 2015;231:1-37.

  17. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160(3):480-98.

  18. Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S, Avolio C, Serviddio G. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11:124.

  19. Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. Eur J Med Chem. 2020;192:112163.

  20. Dash R, Jahan I, Munni YA. Roles of cannabidiol in reversing proteinopathies roles of cannabidiol in reversing proteinopathies. Ageing Res Rev. 2020;65:101209.

  21. Yang H, Zhou J, Lehmann C. GPR55 - A putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27(3):297-302.

  22. Tuduri E, Imbernon M, Hernandez-Bautista RJ, Tojo M, Fern0 J, Dieguez C, Nogueiras R. Gpr55: A new promising target for metabolism? J Mol Endocrinol. 2017;58(3):R191-202.

  23. Guerrero-Alba R, Barragan-Iglesias P, Gonzalez-Hernandez A, Valdez-Morales EE, Granados-Soto V, Condes-Lara M, Rodriguez MG, Marichal-Cancino BA. Some prospective alternatives for treating pain: The endocannabinoid system and its putative receptors GPR18 and GPR55. Front Pharmacol. 2019;8(9):1496.

  24. Cooray R, Gupta V, Suphioglu C. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson's and Alzheimer's diseases: A review. Mol Neurobiol. 2020;57(11):4878-90.

  25. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2017;152(7):1092-101.

  26. Kruger A, Gonjalves Maltarollo V, Wrenger C, Kronen berger T. ADME profiling in drug discovery and a new path paved on silica. Drug Discov Dev. Cambrex High Point, Inc.; 2020.

  27. Wang Y, Xing J, Xu Y, Zhou N, Peng J, Xiong Z, Liu X, Luo X, Luo C, Chen K, Zheng M, Jiang H. In silico AD-ME/T modelling for rational drug design. Q Rev Biophys. 2015;48(4):488-515.

  28. Chen L, Li Y, Zhao Q, Peng H, Hou T. ADME evaluation in drug discovery. 10. Predictions of B-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques. Mol Pharm. 20ll;8(3): 889-900.

  29. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov. 2912;7(10):863-75.

  30. Delaney JS. ESOL: Estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci. 2004;44(3):1000-5.

  31. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.

  32. Cristopher L. Lead profiling lead - and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337-41.

  33. Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the rule of 5 and drugability. Adv Drug Deliv Rev. 2016;101: 89-98.

  34. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;3(7):42717.

  35. Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117-21.

  36. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.

  37. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6(11):881-90.

  38. Lipinski CA. Compound properties and drug quality. In: The practice of medicinal chemistry, 2nd ed. New York: Elsevier; 2003. p. 341-9.

  39. Husain A, Ahmad A, Khan SA, Asif M, Bhutani R, Al-Abbasi FA. Synthesis, molecular properties, toxicity and biological evaluation of some new substituted imidazolidine derivatives in search of potent anti-inflammatory agents. Saudi Pharm J. 2016;24(1):104-14.

  40. Rajasekaran S, Prasad P, Rao GK. iMedPub Journals Molecular Properties and Bio-Activity Score of 2 {[2-(4-chlorophenyl)-4-oxoquinazolin-3(4H)-yl]amino}-N-(substitutedphenyl) acetamides. Int J Drug Dev Res. 2020;3:12-4.

Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)